Company intelligence / Profile preview

Jorna Therapeutics

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Jorna Therapeutics is developing an AI-driven platform, SkyEngine, to design novel RNA-editing therapeutics. The company has entered a major partnership with Ono Pharmaceutical to co-develop new drugs but has not yet reported clinical results or advanced programs into human trials as of May 2025[5].

Therapeutic areas: Rare Diseases
Modalities: RNA editing systemsOligonucleotides[7]Antisense (inferred from focus on RNA editing and oligonucleotide drug discovery)[7]
Industry: Biotech

Partnerships

Ono Pharmaceutical Co., Ltd. – global collaboration for discovery and development of novel RNA-editing drugs using the SkyEngine platform. Ono holds exclusive rights to discover, develop, and commercialize resulting candidates globally[5].

Beyond the preview

Go deeper on Jorna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jorna Therapeutics.